The Board of Directors of Alcami, a CDMO of drug products and provider of analytical testing services, has appointed Patrick D. Walsh as Chairman and Chief Executive Officer (CEO), effective immediately (as reported on March 18, 2021). Mr. Walsh succeeds Walter J. Kaczmarek III, who is stepping down as CEO.

Prior to joining Alcami, Mr. Walsh was co-founder and CEO of TriPharm Services, a parenteral manufacturing business that was acquired by Alcami in January 2020. From 2015 to 2019, Mr. Walsh was the CEO of Avista Pharma, a private equity-backed global provider of contract manufacturing, development, and analytical testing services. From 2010 to 2014, Mr. Walsh served as CEO of AAIPharma Services Corporation, a predecessor company to Alcami.

In addition to his duties at Alcami, Mr. Walsh currently serves as: Chairman of ANI Pharmaceuticals, a Baudette, Minnesota-headquartered pharmaceutical company and provider of CDMO services; a Director at Landec Corporation, a Menlo Park, California-based company that develops health and wellness products; and a Director at Industria Chemica Emiliano, a Reggio Emilia, Italy-based manufacturer of chemicals from bovine bile.

Source: Alcami